Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001178913-21-003918
Filing Date
2021-12-23
Accepted
2021-12-23 16:05:15
Documents
6
Period of Report
2021-12-23

Document Format Files

Seq Description Document Type Size
1 PRE 14A zk2126978.htm PRE 14A 326603
2 image00003.jpg GRAPHIC 6777
3 sc2.jpg GRAPHIC 2276
4 sc3.jpg GRAPHIC 1742
5 sc4.jpg GRAPHIC 5537
6 sc.jpg GRAPHIC 4665
  Complete submission text file 0001178913-21-003918.txt   357227
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

EIN.: 813676773 | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-38807 | Film No.: 211517158
SIC: 2834 Pharmaceutical Preparations